Clinical trial
A Parallel Group, Phase III, Randomized, Observer Blind, Placebo Controlled, Multi Center, Multinational, Multi Arm Study to Demonstrate Non-inferiority of the Immune Response of a Low Dose Compared to the Standard Dose and to Evaluate the Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL)
NCT06705140 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel Group, Phase III, Randomized, Observer Blind, Placebo Controlled, Multi Center, Multinational, Multi Arm Study to Demonstrate Non-inferiority of the Immune Response of a Low Dose Compared to the Standard Dose and to Evaluate the Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL)
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 25, 2024
- Completion date
- June 11, 2025
- Enrollment
- 42 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers, rsv immunisation